Portola Valley, CA, United States of America

Thomas C Merigan

This inventor holds 11 USPTO granted patents. Top assignees: Leland Stanford Junior University, Board of Trustees of Leland Chiron Corporation, The United States of America as Represented by the Department of Health. Active years: 1979-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas C Merigan. Retrieved from https://idiyas.com/inventor/thomas-c-merigan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 90.9

Average Co-Inventor Count = 2.5

ph-index = 8

Forward Citations = 201(Granted Patents)

Company Filing History:

10 out of 5,509

Leland Stanford Junior University

patents

1 out of 1

Board of Trustees of Leland Chiron Corporation

patent

1 out of 1,217

The United States of America as Represented by the Department of Health

patents

where one patent can have more than one assignee

Years Active: 1979-2006

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7129041 - Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome (2006-10-31),

2. 6503705 - Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome (2003-01-07),

3. 5968730 - Polymerase chain reaction assays for monitoring antiviral therapy and (1999-10-19),

4. 5856086 - Polymerase chain reaction assays for monitoring antiviral therapy and (1999-01-05),

5. 5650268 - Polymerase chain reaction assays for monitoring antiviral therapy and (1997-07-22),

6. 5631128 - Polymerase chain reaction assays for monitoring antiviral therapy and (1997-05-20),

7. 5314800 - Purified human cytomegalovirus protein (1994-05-24),

8. 5194256 - Purified human cytomegalovirus protein (1993-03-16),

9. 5149529 - Compositions and treatment for herpes simplex (1992-09-22),

10. 4743562 - Purified human cytomegalovirus protein (1988-05-10),

11. 4140761 - Modification of hepatitis B virus infection in chronic carriers of (1979-02-20),

Title: Thomas C. Merigan: Innovator in Antiviral Therapy

Introduction

Thomas C. Merigan is a prominent inventor based in Portola Valley, CA (US). He has made significant contributions to the field of antiviral therapy, particularly in the treatment of acquired immunodeficiency syndrome (AIDS). With a total of 11 patents, his work has had a profound impact on medical science and patient care.

Latest Patents

One of his latest patents focuses on polymerase chain reaction (PCR) assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of AIDS. This invention relates to methods of monitoring the clinical progression of human immunodeficiency virus (HIV) infection and its response to antiretroviral therapy. According to the invention, PCR assays can predict immunological decline and identify, at an early stage, patients whose infection has become resistant to specific antiretroviral drug regimens.

Career Highlights

Throughout his career, Thomas C. Merigan has worked with esteemed institutions such as Leland Stanford Junior University and the Board of Trustees of Leland Chiron Corporation. His innovative research has paved the way for advancements in the treatment of viral infections, particularly HIV.

Collaborations

Some of his notable coworkers include Michael J. Kozal and Lucy E. Rasmussen. Their collaborative efforts have contributed to the development of groundbreaking methods in antiviral therapy.

Conclusion

Thomas C. Merigan's contributions to the field of antiviral therapy exemplify the importance of innovation in medical science. His work continues to influence the treatment of HIV and improve patient outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]